lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-29. Anything still debated is marked as such rather than presented as settled.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
This self-regulation effect is achieved as the CO2 laser essentially stops ablating as soon as it comes in contact with the intraocular percolated liquid, which occurs as soon as the laser reaches the optimal residual intact layer thickness.
The thus-produced 249Bk has a long half-life of 330 days and thus can capture another neutron. However, the product, 250Bk, again has a relatively short half-life of 3.212 hours and thus does not yield any heavier berkelium isotopes. It instead decays to the californium isotope 250Cf:
== History == Dalbavancin has undergone a phase-III clinical trial for adults with complicated skin infections, but in December 2007, the US Food and Drug Administration (FDA) said more data were needed before approval. Pfizer withdrew its marketing applications to conduct another phase-III clinical trial in September 2008. Durata Therapeutics acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ABSSSIs. Preliminary results in 2012 were promising. About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to vancomycin. In May 2014, dalbavancin was approved for medical use in the United States for ABSSSIs, including MRSA and Streptococcus pyogenes infections.
=== Mass campaigns and high office === Liu retained his political standing through active participation in the state's major mass campaigns. During the land reform movement, Liu announced at a conference that: "I once used to be a big landlord, but now I will unconditionally and unreservedly distribute the land to the peasants." According to Guangming Daily, this statement won him enthusiastic applause from the attendance. In 1955, during the Sufan campaign, Liu called for "greater vigilance" against "counterrevolutionaries". In 1956, he spoke in Chengdu on the occasion of the 90th anniversary of Sun Yat-sen's birth, publicly praising all of the Communist Party's political positions. Politically, he was elected to the 3rd Central Committee of the Revolutionary Committee of the Chinese Kuomintang in 1954, serving until his death. He also served as Minister of Forestry from 1959 to 1967. In this capacity, he made reports on the state of forestry in China and carried out inspections in Jiangxi province as well as other regions. At the second National People's Congress in 1960 during the Great Leap Forward, Liu Wenhui declared that the country was in the midst of a "forestry revolution." Liu Wenhui escaped persecution during the Cultural Revolution due to Zhou Enlai's protection, but he was unable to stop his older brother, Liu Wencai (who had died in 1949), from becoming demonized by state media and remembered in the popular imagination as a tyrannical and corrupt landlord.
==== Other optical imaging ==== For in vivo fluorescence-based optical imaging, dyes that emit near infrared (NIR) wavelengths >700 nm are most effective, such as indocyanine green, but encounter limitations with reduced circulation time and nonspecific interactions with other biological factors that affect the fluorescence. pH-sensitive nanogels with functionalized surface receptors to target cancer cells were loaded with a fluorescent dye that was only released upon endocytosis. These nanogels successfully generated a fluorescent signal from within the cancer cells and many other groups have developed similar technologies.
Sources: en.wikipedia.org
In arguing that West Germany was not "Americanized" after the war, Logemann joins a long debate about American consumer capitalism's power, sweep, and depth of influence in the developed world through the second half of the twentieth century. In pointed contrast to Reinhold Wagnleitner's Coca-colonization and the Cold War (1994) and Victoria de Grazia's Irresistible Empire (2005), Logemann argues that, for all the noisy commentary, pro and con, about postwar Americanization, West Germans shaped their version of the affluent society according to deeply held and distinctly un-American values. Rather than a sweeping homogenization of the developed world, postwar affluence ran along "different paths to consumer modernity" ... Instead of the "consumer-as-citizen" (whom Lizabeth Cohen, in The Consumer's Republic [2003], defined as the main social type in postwar America), West Germans promoted the social consumer who practiced "public consumption," which Logemann defines as "the provision of publicly funded alternatives to private consumer goods and services in areas ranging from housing to transportation or entertainment" (p. 5). The Freakonomics Radio podcast episode "How the Supermarket Helped America Win the Cold War (Ep. 386)" explores the impact that the supermarket had and has on American culture, including the depth of policy decisions by the US Government that impacted agriculture, as well as serving a propaganda weapon against the Soviet Union.
The presidential transition period began following Trump's victory in the 2024 U.S. presidential election, though Trump had chosen Linda McMahon and Howard Lutnick to begin planning for the transition in August 2024. According to The New York Times, Trump was "superstitious" and preferred to avoid discussing the presidential transition process until after Election Day. His transition team relied on the work of the America First Policy Institute, rather than the Heritage Foundation, a conservative think tank that garnered controversy during the election for Project 2025, a set of initiatives that would reshape the federal government. By October, he had not participated in the federal presidential transition process, and he had not signed a required ethics pledge, as of November. During the transition period, Trump announced nominations for his cabinet and administration. Trump was inaugurated on January 20, 2025. He was sworn in by Chief Justice John Roberts. The inauguration occurred indoors in the Capitol Rotunda as a result of a severe cold wave.
=== 2000: Glaxo Wellcome and SmithKline Beecham merger === Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000. The merger was completed on 27 December that year, forming GlaxoSmithKline (GSK). The company's global headquarters were at GSK House, Brentford, London, officially opened in 2002, by then-Prime Minister Tony Blair. The building was erected at a cost of £300 million and as of 2002 was home to 3,000 administrative staff.
Microfluidics allows for the isolation of individual cells for further analyses. The following principles outline the various microfluidic processes for single-cell separation: droplet-in-oil-based isolation, pneumatic membrane valving, and hydrodynamic cell traps. Droplet-in-oil-based microfluidics uses oil-filled channels to hold separated aqueous droplets. This allows the single cell to be contained and isolated from inside the oil-based channels. Pneumatic membrane valves manipulate air pressure to isolate individual cells by membrane deflection. The manipulation of the pressure source allows the opening or closing of channels in a microfluidic network. Typically, the system requires an operator and is limited in throughput.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.